The partnership provides academic research and pharmaceutical development laboratories’expanded access to Good Manufacturing Practices (GMP)-grade, kit-packaged hyaluronic acid and glycosaminoglycan (GAG) products.
By offering premium, clinical grade products to early-stage research investigators, the partnership seeks to bridge the gap between lab-based research, development and commercialization, and accelerate innovation worldwide.
Read more below.
To see our most recent news,
Read more
news from us
-
Press releases May 6, 2024
Acquisition of the Modern Meadow’s human recombinant collagen platform for beauty and biomedical applications
HTL Biotechnology strengthens its position as a global leader in the production and development of pharmaceutical-grade biopolymers by acquiring the beauty and biomedical division of American company Modern Meadow (Nutley, NJ). Notably, this acquisition includes Modern Meadow’s platform of recombinant proteins, with the most advanced product being human recombinant collagen type III (rhCOL3).
-
Articles April 16, 2024
HTL Biotechnology at In-cosmetics Global Congress in Paris
As every year, the In-Cosmetics Global Congress returns to Paris, with top industry leaders and experts gathering under one roof.
This event promises opportunities and insights into the future of Cosmetics. -
Articles April 9, 2024
France BioLead Membership
France BioLead structures, pilots, supports and promotes the French biomanufacturing sector.